Trial Outcomes & Findings for Combination Primary Care and Prevention Services for Women Who Inject Drugs and Exchange Sex in Seattle, Washington (NCT NCT06187064)
NCT ID: NCT06187064
Last Updated: 2026-02-20
Results Overview
Proportion of participants who initiate PrEP
COMPLETED
NA
50 participants
6 months
2026-02-20
Participant Flow
Participant milestones
| Measure |
Study Cohort
The investigators will enroll 50 female-identifying people who present to the clinical van for care and follow them for 6 months.
|
|---|---|
|
Overall Study
STARTED
|
50
|
|
Overall Study
COMPLETED
|
50
|
|
Overall Study
NOT COMPLETED
|
0
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
Combination Primary Care and Prevention Services for Women Who Inject Drugs and Exchange Sex in Seattle, Washington
Baseline characteristics by cohort
| Measure |
Study Cohort
n=50 Participants
The investigators will enroll 50 female-identifying people who present to the clinical van for care and follow them for 6 months.
|
|---|---|
|
Age, Continuous
|
35 years
n=14 Participants
|
|
Sex/Gender, Customized
Woman
|
50 Participants
n=14 Participants
|
|
Race/Ethnicity, Customized
American Indian or Alaska Native
|
3 Participants
n=14 Participants
|
|
Race/Ethnicity, Customized
Asian
|
2 Participants
n=14 Participants
|
|
Race/Ethnicity, Customized
Black or African American
|
3 Participants
n=14 Participants
|
|
Race/Ethnicity, Customized
Hispanic or Latina
|
3 Participants
n=14 Participants
|
|
Race/Ethnicity, Customized
Multiracial
|
11 Participants
n=14 Participants
|
|
Race/Ethnicity, Customized
Native Hawaiian or Other Pacific Islander
|
0 Participants
n=14 Participants
|
|
Race/Ethnicity, Customized
White
|
28 Participants
n=14 Participants
|
|
Region of Enrollment
United States
|
50 Participants
n=14 Participants
|
PRIMARY outcome
Timeframe: 6 monthsProportion of participants who initiate PrEP
Outcome measures
| Measure |
Study Cohort
n=50 Participants
The investigators will enroll 50 female-identifying people who present to the clinical van for care and follow them for 6 months.
|
|---|---|
|
Evaluate Uptake of Pre-exposure Prophylaxis (PrEP)
|
10 Participants
|
PRIMARY outcome
Timeframe: 6 monthsProportion of participants who initiate MOUD
Outcome measures
| Measure |
Study Cohort
n=50 Participants
The investigators will enroll 50 female-identifying people who present to the clinical van for care and follow them for 6 months.
|
|---|---|
|
Evaluate Uptake of Medications for Opioid Use Disorder (MOUD)
|
21 Participants
|
OTHER_PRE_SPECIFIED outcome
Timeframe: 6 monthsProportion of participants who achieve continued use of PrEP and/or MOUD
Outcome measures
Outcome data not reported
OTHER_PRE_SPECIFIED outcome
Timeframe: 6 monthsProportion of participants who complete STI treatment following a reactive/positive STI test
Outcome measures
Outcome data not reported
OTHER_PRE_SPECIFIED outcome
Timeframe: 6 monthsTime from reactive/positive STI test to completion of STI treatment
Outcome measures
Outcome data not reported
OTHER_PRE_SPECIFIED outcome
Timeframe: 6 monthsProportion of participants who agree that care model is safe and that their health improved getting care from a mobile clinic
Outcome measures
Outcome data not reported
OTHER_PRE_SPECIFIED outcome
Timeframe: 6 monthsProportion of participants who agree that they felt comfortable getting and/or prefer POC STI testing
Outcome measures
Outcome data not reported
Adverse Events
Study Cohort
Serious adverse events
| Measure |
Study Cohort
n=50 participants at risk
The investigators will enroll 50 female-identifying people who present to the clinical van for care and follow them for 6 months.
|
|---|---|
|
General disorders
Hospitalizations
|
26.0%
13/50 • Up to 6 months post-enrollment.
Adverse events were collected using a medical chart review.
|
Other adverse events
Adverse event data not reported
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place